KEYNOTE-183 trial of pembrolizumab in multiple myeloma: trial design and rationale
Overview of CLL therapies and sequencing of therapies
CLL update from ICML17: Current treatment and future directions for patients
How can we overcome ibrutinib resistance?
Relapse in DLBCL - addressing the unmet need with brentuximab vedotin